Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00351884 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Vildagliptin 100 MG as Compared to Placebo as Add-on to Metformin in Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 370
- Enrollment target
NCT00351884 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 370 participants.
The verdict
NCT00351884, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 370 participants
- Enrollment target
Study Summary
Vildagliptin is an oral anti-diabetic agent. This is a 24-week study to assess the efficacy on HbA1c of 100 mg vildagliptin once daily as compared to placebo as add-on to metformin in patients with type 2 diabetes inadequately controlled with metformin.
Interventions
- DRUG placebo
- DRUG Vildagliptin AM
- DRUG vildagliptin pm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 370 participants |
| Start Date | 2006-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00351884
The ClinicalTrials.gov registry entry for NCT00351884 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 370 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00351884 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00351884 about?
NCT00351884 is a clinical study titled "Efficacy of Vildagliptin 100 MG as Compared to Placebo as Add-on to Metformin in Patients With Type 2 Diabetes". Vildagliptin is an oral anti-diabetic agent. This is a 24-week study to assess the efficacy on HbA1c of 100 mg vildagliptin once daily as compared to placebo as add-on to metformin in patients with type 2 diabetes inadequately controlled with metformin.
What is the current status of trial NCT00351884?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 370 participants. The study started on 2006-05.
What interventions are being tested in trial NCT00351884?
The interventions under investigation include: placebo (DRUG), Vildagliptin AM (DRUG), vildagliptin pm (DRUG).
Who is sponsoring clinical trial NCT00351884?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.